Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
07
08
2023
accepted:
09
10
2023
medline:
18
12
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
A toxicity-reduced conditioning regimen with treosulfan, fludarabine, and thiotepa in patients with high-risk β-thalassemia major has significantly improved hematopoietic stem cell transplantation (HCT) outcomes. However, complications resulting from regimen-related toxicities (RRTs), mixed chimerism, and graft rejection remain a challenge. We evaluated the dose-exposure-response relationship of treosulfan and its active metabolite S, S-EBDM, in a uniform cohort of patients with β-thalassemia major to identify whether therapeutic drug monitoring (TDM) and dose adjustment of treosulfan is feasible. Plasma treosulfan/S, S-EBDM levels were measured in 77 patients using a validated liquid chromatography with tandem mass spectrometry method, and the pharmacokinetic parameters were estimated using nlmixr2. The influence of treosulfan and S, S-EBDM exposure, and GSTA1/NQO1 polymorphisms on graft rejection, RRTs, chimerism status, and 1-year overall survival (OS), and thalassemia-free survival (TFS) were assessed. We observed that treosulfan exposure was lower in patients with graft rejection than those without (1,655 vs. 2,037 mg•h/L, P = 0.07). Pharmacodynamic modeling analysis to identify therapeutic cutoff revealed that treosulfan exposure ≥1,660 mg•hour/L was significantly associated with better 1-year TFS (97% vs. 81%, P = 0.02) and a trend to better 1-year OS (90% vs. 69%, P = 0.07). Further, multivariate analysis adjusting for known pre-HCT risk factors also revealed treosulfan exposure <1,660 mg•h/L (hazard ratio (HR) = 3.23; 95% confidence interval (CI) = 1.12-9.34; P = 0.03) and GSTA1*B variant genotype (HR = 3.75; 95% CI = 1.04-13.47; P = 0.04) to be independent predictors for inferior 1-year TFS. We conclude that lower treosulfan exposure increases the risk of graft rejection and early transplant-related mortality affecting TFS. As no RRTs were observed with increasing treosulfan exposure, TDM-based dose adjustment could be feasible and beneficial.
Substances chimiques
treosulfan
CO61ER3EPI
Busulfan
G1LN9045DK
Thiotepa
905Z5W3GKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-125Subventions
Organisme : Medical Research Council
ID : MR/M008665/1
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Beelen, D.W. et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am. J. Hematol. 97, 1023-1034 (2022).
Malagola, M. et al. Busulfan or Treosulfan conditioning platform for allogeneic stem cell transplantation in patients aged >60 Y with acute myeloid leukemia/myelodysplastic syndrome: a subanalysis of the GITMO AlloEld study. Transplant. Direct 9, e1451 (2023).
Kalwak, K. et al. Treosulfan-fludarabine-thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies. Bone Marrow Transplant. 55, 1996-2007 (2020).
Gran, C. et al. Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the chronic malignancies working party of the EBMT. Br. J. Haematol. 189, e213-e217 (2020).
Slatter, M.A. et al. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 50, 1536-1541 (2015).
Slatter, M.A. et al. Treosulfan and fludarabine conditioning for hematopoietic stem cell transplantation in children with primary immunodeficiency: UK experience. Biol. Blood Marrow Transplant. 24, 529-536 (2018).
Feit, P.W., Rastrup-Andersen, N. & Matagne, R. Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate. J. Med. Chem. 13, 1173-1175 (1970).
Pai, A.A. et al. Genetic variants in drug metabolizing and transporter genes explain variability in fludarabine pharmacokinetics in patients undergoing HSCT. Biol. Blood Marrow Transplant. 24, S80 (2018).
Thuret, I., Ruggeri, A., Angelucci, E. & Chabannon, C. Hurdles to the adoption of gene therapy as a curative option for transfusion-dependent thalassemia. Stem Cells Transl. Med. 11, 407-414 (2022).
Oikonomopoulou, C. & Goussetis, E. HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe. Bone Marrow Transplant. 56, 2882-2888 (2021).
Algeri, M., Lodi, M. & Locatelli, F. Hematopoietic stem cell transplantation in thalassemia. Hematol. Oncol. Clin. North Am. 37, 413-432 (2023).
Mathews, V. et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 13, 889-894 (2007).
Mathews, V. et al. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PloS One 8, e61637 (2013).
George, B. et al. Treosulfan based conditioning regimen is associated with better overall survival compared to busulfan based regimens in older children with Thalassaemia major. Biol. Blood Marrow Transplant. 25, S317-S318 (2019).
George, B. et al. Increased incidence of mixed chimerism with the use of fludarabine-Treosulfan based conditioning in patients undergoing allogeneic stem cell transplantation for Thalassaemia major. Biol. Blood Marrow Transplant. 21, S284-S285 (2015).
van der Stoep, M.Y.E.C. et al. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study. Br. J. Haematol. 179, 772-780 (2017).
Chiesa, R. et al. Proposed therapeutic range of Treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial. Clin. Pharmacol. Ther. 108, 264-273 (2019).
van der Stoep, M.Y.E.C. et al. Impact of Treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: a prospective multicenter study. Transplant. Cell. Ther. 28, 99.e1-99.e7 (2022).
Romański, M., Pogorzelska, A. & Główka, F.K. Kinetics of in vitro guanine-N7-alkylation in calf thymus DNA by (2S,3S)-1,2-Epoxybutane-3,4-diol 4-methanesulfonate and (2S,3S)-1,2:3,4-diepoxybutane: revision of the mechanism of DNA cross-linking by the prodrug treosulfan. Mol. Pharm. 16, 2708-2718 (2019).
Sellathamby, S. et al. Developing an algorithm of informative markers for evaluation of chimerism after allogeneic bone marrow transplantation. Bone Marrow Transplant. 37, 751-755 (2006).
Mohanan, E. et al. Pharmacokinetics and pharmacodynamics of Treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem cell transplantation. Clin. Pharmacol. Ther. 104, 575-583 (2018).
Romański, M., Teżyk, A., Żaba, C. & Główka, F.K. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue. Talanta 127, 123-132 (2014).
Fouzia, N.A. et al. Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide. Bone Marrow Transplant. 53, 169-174 (2018).
Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) <https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60>.
The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies (Springer, Cham, 2019) <http://www.ncbi.nlm.nih.gov/books/NBK553942/>.
Jain, A. et al. IndiGenomes: a comprehensive resource of genetic variants from over 1000 Indian genomes. Nucleic Acids Res. 49, D1225-D1232 (2021).
Główka, F.K., Romański, M., Teżyk, A. & Żaba, C. Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers. J. Pharm. Biomed. Anal. 72, 145-149 (2013).
Ten Brink, M.H. et al. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation. Ther. Drug Monit. 36, 465-472 (2014).
Koyyalamudi, S.R. et al. Development and validation of a high pressure liquid chromatography-UV method for the determination of Treosulfan and its epoxy metabolites in human plasma and its application in pharmacokinetic studies. J. Chromatogr. Sci. 54, 326-333 (2016).
Główka, F.K., Karaźniewicz-Łada, M., Grund, G., Wróbel, T. & Wachowiak, J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant. 42(Suppl 2), S67-S70 (2008).
Danielak, D., Twardosz, J., Kasprzyk, A., Wachowiak, J., Kałwak, K. & Główka, F. Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation. Eur. J. Clin. Pharmacol. 74, 79-89 (2018).
Beelen, D.W. et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 35, 233-241 (2005).
Nemecek, E.R. et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol. Blood Marrow Transplant. 17, 341-350 (2011).
Główka, F. et al. Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT. Eur. J. Pharm. Sci. 68, 87-93 (2015).
Romański, M., Kasprzyk, A., Karbownik, A., Szałek, E. & Główka, F.K. Formation rate-limited pharmacokinetics of biologically active epoxy transformers of prodrug Treosulfan. J. Pharm. Sci. 105, 1790-1797 (2016).
Danielak, D., Kasprzyk, A., Wróbel, T., Wachowiak, J., Kałwak, K. & Główka, F. Relationship between exposure to treosulfan and its monoepoxytransformer-an insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation. Eur. J. Pharm. Sci. 120, 1-9 (2018).
Chiesa, R. et al. Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial. Clin. Pharmacol. Ther. 108, 264-273 (2020).
Rosser, S.P.A. et al. Evaluation of treosulfan cumulative exposure in paediatric patients through population pharmacokinetics and dosing simulations. Br. J. Clin. Pharmacol. 89, 1413-1424 (2023).
van der Stoep, M.Y.E.C. et al. Effect of busulfan and treosulfan on gonadal function after allogeneic stem cell transplantation in children and adolescents with nonmalignant diseases is not exposure-dependent. Transplant. Cell. Ther. 29, 529.e1-529.e5 (2023).
Ansari, M. et al. Glutathione S-transferase gene variations influence BU pharmacokinetics and outcome of hematopoietic SCT in pediatric patients. Bone Marrow Transplant. 48, 939-946 (2013).
Ansari, M. et al. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplant. 51, 377-383 (2016).
Ansari, M. et al. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget 8, 90852-90867 (2017).
Kim, I. et al. Glutathione S-transferase A1 polymorphisms and acute graft-vs.-host disease in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Clin. Transplant. 21, 207-213 (2007).
Romański, M. & Główka, F.K. In vitro study of the enzymatic and nonenzymatic conjugation of Treosulfan with glutathione. Eur. J. Drug Metab. Pharmacokinet. 44, 653-657 (2019).
Pai, A.A. et al. 207 - glutathione S-transferase gene promoter polymorphism (GSTA1*B) influences Haematopoietic cell transplantation (HCT) outcome in patients with β-thalassemia receiving treosulfan/fludarabine/thiotepa regimen. Transplant. Cell. Ther. 29, S160-S161 (2023).
Yuan, J. et al. Optimization of busulfan dosing regimen in pediatric patients using a population pharmacokinetic model incorporating GST mutations. Pharmgenomics Pers. Med. 14, 253-268 (2021).